In-Silico PBPK Modeling and Simulation

In-Silico PBPK Modeling and Simulation

After completing molecule's basic benchwork and characterization, it is time to leverage powerful simulation software for in vitro-in vivo extrapolation.

Integrating in silico advancements into program will help consumer expedite timeline for CMC (chemistry, manufacturing, and controls) and dosing strategies. We can identify absorption risks in the early development and optimize preclinical and clinical dosing strategies.

Crystal pharmatech offers PBPK modeling and simulation in drug research and development consulting services using GastroPlus® software – the pharmaceutical industry's most sophisticated platform for the prediction of drug absorption and disposition in human and animal species. We can extrapolate in silico predictions for:

Solubility

pKa

Absorption

Metabolism

Transport

Shortening your clinical development timeline with in silico FIH dose selection and formulation optimization is possible and can improve the following:

Tissue-specific solubility (in vivo solubilities within different tissue environments)

Non-compartmental, analysis-based modeling

Algorithmic determination per species, formulation, and dosing route (oral and injectable)

If you want to know more about physiologically based pharmacokinetic, please visit our website.

As a cdmo pharma company, we will do our best to meet all the needs of clients.

Crystal Pharmatech, founded in 2010, is a global contract research organization with approximately 300 employees and four R&D centers in New Jersey (USA), San Francisco (USA), Toronto (Canada), and Suzhou (China). Collectively, these sites provide integrated support for pharmaceutical and biotechnology companies worldwide. We offer API solid-state research, crystallization, preformulation, formulation development and manufacturing, clinical supply, bioanalytical and biomarker testing, biologics CMC analytics, and clinical pharmacology.